[
  {
    "ts": null,
    "headline": "CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation",
    "summary": "March 14 - * CMS: DEALS SIGNED WITH MANUFACTURERS OF 15 DRUGS COVEREDUNDERMEDICARE PART D SELECTED FOR SECOND CYCLE OF MEDICARE DRUG PRICENEGOTIATION PROGRAM ...",
    "url": "https://finnhub.io/api/news?id=9ab3d8ef646f1da11ca00a4ee1d9b52751ab4c4c677a8fbbcef5020b2a4b4f34",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741975011,
      "headline": "CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation",
      "id": 133175195,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "March 14 - * CMS: DEALS SIGNED WITH MANUFACTURERS OF 15 DRUGS COVEREDUNDERMEDICARE PART D SELECTED FOR SECOND CYCLE OF MEDICARE DRUG PRICENEGOTIATION PROGRAM ...",
      "url": "https://finnhub.io/api/news?id=9ab3d8ef646f1da11ca00a4ee1d9b52751ab4c4c677a8fbbcef5020b2a4b4f34"
    }
  },
  {
    "ts": null,
    "headline": "Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer",
    "summary": "Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to start by mid-year, the analyst tells investors in a research note. The firm thinks the trial has a “decent chance at working,” but does not currently view Descartes-08 as a commercially viable therapy. Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six mo",
    "url": "https://finnhub.io/api/news?id=63ea05795c05ca2dc829282a0050debad24683bf6e4645b656f89a6c16a157e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741968914,
      "headline": "Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer",
      "id": 133185002,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to start by mid-year, the analyst tells investors in a research note. The firm thinks the trial has a “decent chance at working,” but does not currently view Descartes-08 as a commercially viable therapy. Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six mo",
      "url": "https://finnhub.io/api/news?id=63ea05795c05ca2dc829282a0050debad24683bf6e4645b656f89a6c16a157e3"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN - UPLIZNA SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
    "summary": "THOUSAND OAKS - Amgen today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA in adults living with generalized myasthenia gravis .The...",
    "url": "https://finnhub.io/api/news?id=d2785eea749feebe4c745eb96ad3e586fb8742f8106763a10d450687d399cdaa",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741950022,
      "headline": "AMGEN - UPLIZNA SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
      "id": 133169280,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "THOUSAND OAKS - Amgen today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA in adults living with generalized myasthenia gravis .The...",
      "url": "https://finnhub.io/api/news?id=d2785eea749feebe4c745eb96ad3e586fb8742f8106763a10d450687d399cdaa"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
    "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
    "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741945228,
      "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
      "id": 133168922,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
      "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c"
    }
  }
]